[ad_1]
The pharmaceutical company AstraZeneca will carry out a joint study with Russia’s NF Gamaleya Research Center, Russia’s Direct Investment Fund and the R-Pharm Group to combine its own coronavirus vaccine with Sputnik V. This was announced by the AstraZeneca Russian branch, cited by Agence France-Presse.
Recently, Sanofi, which is working on the vaccine with GSK, said it plans to launch the latest human trials in late December, recalls AFP. The program provides an evaluation of the safety and immunity of the combined use of the two vaccines.
Volunteers over the age of 18 will participate in the research, according to the British-Swedish company.
Meanwhile, the French pharmaceutical corporation Sanofi and the British GSK announced today that the vaccine they are developing against COVID-19 will be ready only at the end of 2021, after receiving results below expectations from the first clinical trials, reported AFP.
The course of the program “is slow to improve immune responses in the elderly,” the companies said in a general statement. They expect the drug to be available only in the last quarter of next year, although they initially hoped to seek approval in the first quarter and administer 1 billion doses in 2021.
Currently, the immune response in people ages 18 to 49 is “comparable to that of patients recovering from COVID-19 infection,” but “insufficient” in the elderly, according to the statement.
[ad_2]
